1. Imran M, Kumar Arora M, Asdaq SM, Khan SA, Alaqel SI, Alshammari MK, Alshehri MM, Alshrari AS, Mateq Ali A, Al-Shammeri AM, Alhazmi BD. Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19. Molecules. 2021 Jan;26(19):5795.
2. Fischer WA, Eron JJ, Holman W, Cohen MS, Fang L, Szewczyk LJ, Sheahan TP, Baric RS, Mollan KR, Wolfe CR, Duke ER. Molnupiravir, an Oral Antiviral Treatment for COVID-19. medRxiv. 2021 Jan 1.
3. Shu B, Gong P. Structural basis of viral RNA-dependent RNA polymerase catalysis and translocation. Proc Natl Acad Sci U S A. 2016 Jul 12; 113(28):E4005-14.
4. Imran M, Alshrari AS, Asdaq SMB, Abida. Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review. J Infect Public Health. 2021 Aug; 14(8):1075-1086.
5. Ghasemnejad-Berenji M, Pashapour S. Favipiravir and COVID-19: A Simplified Summary. Drug Res (Stuttg). 2021 Mar; 71(3):166-170.
6. Wang Y, Anirudhan V, Du R, Cui Q, Rong L. RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target. J Med Virol. 2021 Jan; 93(1):300-310.
7. Vicenti I, Zazzi M, Saladini F. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. Expert Opin Ther Pat. 2021 Apr; 31(4):325-337
8. Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut NCJE, Morin MJ, Szewczyk LJ, Painter GR. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2. Antimicrob Agents Chemother. 2021 Mar 1; 65(5) :e02428-20.
9. Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nature microbiology. 2021 Jan;6(1):11-8.
10. Abdelnabi R, Foo CS, De Jonghe S, Maes P, Weynand B, Neyts J. Molnupiravir inhibits replication of the emerging SArS-CoV-2 Straints of Concern in a Hamster infection Model. The Journal of infectious diseases. 2021 Sep 1;224(5):749-53.
11. Khoo SH, Fitzgerald R, Fletcher T, et al. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. J Antimicrob Chemother. 2021;dkab318. doi:10.1093/jac/dkab318
12. Szewczyk L. The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID). Clinical Trials. 2021. Available from: https://clinicaltrials.gov/ct2/show/record/NCT04405739?cond=Molnupiravir&draw=2&rank=1&view=record
13. MERCK. Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study. MERCK. 2021. Available from: https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/
Facebook 
Masuk dengan Email
